Live Breaking News & Updates on Magnetismm 3 Trial

Stay updated with breaking news from Magnetismm 3 trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm. ....

Emory University , United States , Ashling Wahner , Ajayk Nooka , Myeloma Program , Oncology At Emory University School Of Medicine , Department Of Hematology , Medical Oncology , Emory University School , Winship Data , Technology Applications Shared Resource , Winship Cancer Institute , Apple Podcasts , Google Podcasts , Amazon Music , Fda Approval Of Elranatamab , Relapsed Refractory Multiple Myeloma , Magnetismm 3 Trial ,

Dr Mohty on Bispecific Antibodies in R/R Multiple Myeloma

Mohamad Mohty, MD, PhD, discusses unmet needs in patients with relapsed/refractory multiple myeloma and the rationale for investigating elranatamab monotherapy in this population in the phase 2 MagnetisMM-3 trial. ....

Mohamad Mohty , Sorbonne University , Cellular Therapy Department , Saint Antoine Hospital , Patients With Relapsed Refractory Multiple Myeloma , Magnetismm 3 Trial , Saint Antoine Hospital And Sorbonne University ,